<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00110916</url>
  </required_header>
  <id_info>
    <org_study_id>20040100</org_study_id>
    <nct_id>NCT00110916</nct_id>
  </id_info>
  <brief_title>Treatment for Patients With Osteoarthritis (OA) of the Knee</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Intra-Articular metHuIL-1ra (Anakinra) in Subjects With Osteoarthritis (OA) of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the clinical response in subjects with symptomatic
      OA of the knee following a single 50 mg anakinra, 150 mg anakinra or placebo intra-articular
      (IA) injection.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <completion_date type="Actual">February 2005</completion_date>
  <primary_completion_date type="Actual">February 2005</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>WOMAC</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain Patient's global assessment</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">165</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>Anakinra</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>anakinra</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intra-articular metHuIL-1ra (anakinra)</intervention_name>
    <description>anakinra</description>
    <arm_group_label>Anakinra</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: - Diagnosed with knee OA as determined by American College of
        Rheumatology (ACR) criteria - Pain defined by a level of greater than 30 mm on a 100 mm
        Visual Analogue Scale (VAS) - No evidence of active effusion or inflammatory flare,
        confirmed by investigator - Must exhibit radiographic evidence of tibio-femoral compartment
        knee OA within 12 months of screening - Stable doses of any non-prescribed supplements
        (e.g. glucosamine or chondroitin sulphate, shark cartilage, diacerhein, soya extract) for
        at least 2 months prior to screening - Unchanged use of physical therapy, biomechanical
        devices or orthotic support within at least 2 months of screening - Subjects on
        nonsteroidal anti-inflammatory drug (NSAID) therapy must discontinue NSAIDs 3 days prior to
        baseline (Day 1) - Before any study-specific procedure is performed, the appropriate
        written informed consent for participation in the study must be obtained Exclusion
        Criteria: - Malignancy within the previous 5 years, except for basal cell or in situ cancer
        - Significant hematologic disease - Active infection or history of recurrent or chronic
        infections - Known diagnosis of HIV, hepatitis B, or hepatitis C infection - Uncontrolled
        diabetes or cardiovascular disease and hypertension - Inflammatory arthropathy including
        secondary OA - Isolated OA of the patellofemoral joint (bi or tri-compartmental involvement
        are not exclusions) - End-stage (&quot;bone-on-bone&quot;) OA (Kellgren Lawrence score of 4) - OA of
        the hip ipsilateral to the index knee - Total white cell count less than 2.0 x 109/L and/or
        platelet count less than 100 x 109/L observed within 1 month preceding screening - Prior IA
        injection of anakinra or experimental interleukin-1 (IL-1) inhibitor therapy - Concurrent
        treatment with subcutaneous (SC) anakinra - Concurrent or recent (less than or equal to 1
        month) use of experimental therapy - Prior IA corticosteroid injection within 1 month of
        study - Prior viscosupplement therapy within 3 months of study - Contraindication(s) to IA
        injections - Subjects who are pregnant or breast-feeding, or plan to become pregnant during
        the study - Subject is not using adequate contraception - Known allergy to E coli-derived
        products - Unable to understand informed consent - Concerns regarding subject's compliance
        with the protocol procedures - Subject will not be available for follow-up assessment -
        Active substance abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>February 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2005</study_first_submitted>
  <study_first_submitted_qc>May 16, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2005</study_first_posted>
  <last_update_submitted>February 20, 2008</last_update_submitted>
  <last_update_submitted_qc>February 20, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 22, 2008</last_update_posted>
  <responsible_party>
    <name_title>Global Development Leader</name_title>
    <organization>Amgen Inc.</organization>
  </responsible_party>
  <keyword>Intra-articular</keyword>
  <keyword>Osteoarthritis</keyword>
  <keyword>OA</keyword>
  <keyword>anakinra</keyword>
  <keyword>Amgen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

